So-Young Reports Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results
So-Young International (SY) reported its Q4 and FY2024 financial results, showing mixed performance. Q4 total revenues decreased 5.5% to RMB369.2 million (US$50.6 million) compared to 2023. The company recorded a significant net loss of RMB607.6 million (US$83.2 million), primarily due to a one-time goodwill impairment charge of RMB540.0 million for Wuhan Miracle subsidiary.
Notable operational highlights include the expansion to 19 aesthetic centers across nine major cities, with 11 centers achieving positive monthly operating cash flow. Aesthetic treatment services revenue grew substantially by 701.6% to RMB81.3 million. The company maintains a 60% customer retention rate and served over 1,200 institutions with supply chain solutions.
The board declared a special cash dividend of US$0.03445 per ordinary share (US$0.0265 per ADS), with approximately US$3 million total distribution planned for April 25, 2025.
So-Young International (SY) ha riportato i risultati finanziari del Q4 e dell'anno fiscale 2024, mostrando una performance mista. I ricavi totali del Q4 sono diminuiti del 5,5% a RMB369,2 milioni (US$50,6 milioni) rispetto al 2023. L'azienda ha registrato una significativa perdita netta di RMB607,6 milioni (US$83,2 milioni), principalmente a causa di un'imposta una tantum per impairment di goodwill di RMB540,0 milioni per la controllata Wuhan Miracle.
Tra i risultati operativi significativi c'è l'espansione a 19 centri estetici in nove grandi città, con 11 centri che hanno raggiunto un flusso di cassa operativo mensile positivo. I ricavi dei servizi di trattamento estetico sono cresciuti notevolmente del 701,6% a RMB81,3 milioni. L'azienda mantiene un tasso di fidelizzazione dei clienti del 60% e ha servito oltre 1.200 istituzioni con soluzioni di supply chain.
Il consiglio ha dichiarato un dividendo speciale in contante di US$0,03445 per azione ordinaria (US$0,0265 per ADS), con una distribuzione totale di circa US$3 milioni pianificata per il 25 aprile 2025.
So-Young International (SY) informó sus resultados financieros del Q4 y del año fiscal 2024, mostrando un rendimiento mixto. Los ingresos totales del Q4 disminuyeron un 5.5% a RMB369.2 millones (US$50.6 millones) en comparación con 2023. La compañía registró una pérdida neta significativa de RMB607.6 millones (US$83.2 millones), principalmente debido a un cargo por deterioro de goodwill único de RMB540.0 millones para su filial Wuhan Miracle.
Entre los aspectos operativos destacados se incluye la expansión a 19 centros estéticos en nueve ciudades importantes, con 11 centros logrando flujo de caja operativo mensual positivo. Los ingresos por servicios de tratamientos estéticos crecieron sustancialmente un 701.6% a RMB81.3 millones. La empresa mantiene una tasa de retención de clientes del 60% y ha atendido a más de 1,200 instituciones con soluciones de cadena de suministro.
La junta declaró un dividendo especial en efectivo de US$0.03445 por acción ordinaria (US$0.0265 por ADS), con una distribución total de aproximadamente US$3 millones planeada para el 25 de abril de 2025.
So-Young International (SY)는 2024년 4분기 및 연간 재무 결과를 발표하며 혼합된 성과를 보여주었습니다. 4분기 총 수익은 2023년 대비 5.5% 감소한 RMB369.2백만 (US$50.6백만)으로 나타났습니다. 회사는 Wuhan Miracle 자회사의 일회성 goodwill 손상 차감으로 인해 RMB607.6백만 (US$83.2백만)의 상당한 순손실을 기록했습니다.
주목할 만한 운영 하이라이트로는 9개 주요 도시에서 19개의 미용 센터로 확장한 것이 있으며, 11개 센터는 긍정적인 월 운영 현금 흐름을 달성했습니다. 미용 치료 서비스 수익은 701.6% 증가하여 RMB81.3백만에 달했습니다. 회사는 60%의 고객 유지율을 유지하고 있으며, 1,200개 이상의 기관에 공급망 솔루션을 제공했습니다.
이사회는 특별 현금 배당금으로 보통주 1주당 US$0.03445 (ADS당 US$0.0265)를 선언했으며, 2025년 4월 25일에 약 US$3백만의 총 배당금 분배를 계획하고 있습니다.
So-Young International (SY) a publié ses résultats financiers pour le 4ème trimestre et l'exercice 2024, montrant une performance mitigée. Les revenus totaux du 4ème trimestre ont diminué de 5,5 % pour atteindre 369,2 millions de RMB (50,6 millions de dollars US) par rapport à 2023. L'entreprise a enregistré une perte nette significative de 607,6 millions de RMB (83,2 millions de dollars US), principalement en raison d'une charge unique d'amortissement de goodwill de 540,0 millions de RMB pour sa filiale Wuhan Miracle.
Parmi les points forts opérationnels notables, on trouve l'expansion à 19 centres esthétiques dans neuf grandes villes, avec 11 centres atteignant un flux de trésorerie opérationnel mensuel positif. Les revenus des services de traitement esthétique ont considérablement augmenté de 701,6 % pour atteindre 81,3 millions de RMB. L'entreprise maintient un taux de fidélisation des clients de 60 % et a servi plus de 1 200 institutions avec des solutions de chaîne d'approvisionnement.
Le conseil a déclaré un dividende spécial en espèces de 0,03445 $ US par action ordinaire (0,0265 $ US par ADS), avec une distribution totale d'environ 3 millions de dollars US prévue pour le 25 avril 2025.
So-Young International (SY) hat seine finanziellen Ergebnisse für das 4. Quartal und das Geschäftsjahr 2024 veröffentlicht, die eine gemischte Leistung zeigen. Die Gesamteinnahmen im 4. Quartal sanken um 5,5% auf RMB369,2 Millionen (US$50,6 Millionen) im Vergleich zu 2023. Das Unternehmen verzeichnete einen erheblichen Nettoverlust von RMB607,6 Millionen (US$83,2 Millionen), hauptsächlich aufgrund einer einmaligen Wertminderung von RMB540,0 Millionen für die Tochtergesellschaft Wuhan Miracle.
Zu den bemerkenswerten betrieblichen Höhepunkten gehört die Expansion auf 19 ästhetische Zentren in neun großen Städten, wobei 11 Zentren einen positiven monatlichen operativen Cashflow erzielt haben. Die Einnahmen aus ästhetischen Behandlungsdiensten stiegen erheblich um 701,6% auf RMB81,3 Millionen. Das Unternehmen hält eine Kundenbindungsrate von 60% und hat über 1.200 Institutionen mit Lösungen in der Lieferkette bedient.
Der Vorstand erklärte eine sonstige Bar-Dividende von US$0,03445 pro Stammaktie (US$0,0265 pro ADS), wobei eine Gesamtverteilung von etwa US$3 Millionen für den 25. April 2025 geplant ist.
- 701.6% growth in aesthetic treatment services revenue to RMB81.3 million
- 11 out of 19 aesthetic centers achieving positive monthly operating cash flow
- 60% customer retention rate maintained
- Special dividend declaration of US$3 million to shareholders
- Net loss of RMB607.6 million in Q4 2024, compared to net income of RMB17.5 million in Q4 2023
- 5.5% decrease in total Q4 revenues to RMB369.2 million
- 27.7% decline in information and reservation services revenue
- RMB540.0 million one-time goodwill impairment charge for Wuhan Miracle subsidiary
Insights
So-Young's Q4 and fiscal 2024 results reveal a company in strategic transition with mixed financial performance. The headline net loss of RMB607.6 million is concerning but requires context - it's primarily driven by a one-time RMB540 million goodwill impairment related to Wuhan Miracle subsidiary.
Core revenue trends show the company's pivot is gaining traction. While total Q4 revenue declined 5.5% YoY to
The center network expansion shows promising metrics: 19 aesthetic centers across nine cities, with 11 already generating positive monthly operating cash flow and
Cost structure analysis reveals the transition's financial dynamics - information services costs decreased
The declaration of a
So-Young's transformation remains in early stages, with profitability challenges as they build scale in their direct operations. The non-GAAP Q4 loss of
Fourth Quarter 2024 Financial Highlights
- Total revenues were
RMB369.2 million (US [1]), compared with$50.6 million RMB390.6 million in the corresponding period of 2023, in line with previous guidance. - Net loss attributable to So-Young International Inc. was
RMB607.6 million (US ), compared with net income attributable to So-Young International Inc. of$83.2 million RMB17.5 million in the same period of 2023, primarily driven by a one-time goodwill impairment charge ofRMB540.0 million (US ) for the Company's subsidiary, Wuhan Miracle.$74.0 million - Non-GAAP net loss attributable to So-Young International Inc.[2] was
RMB53.2 million (US ), compared with non-GAAP net income attributable to So-Young International Inc. of$7.3 million RMB35.7 million in the same period of 2023.
Fourth Quarter 2024 Operational Highlights
- The aggregate value of medical aesthetic treatment transactions facilitated by So-Young's platform was
RMB356.6 million , compared withRMB470.9 million in the same period of 2023. - Number of verified paid visits for the quarter reached over 39,500, compared with approximately 2,300 in the same period of 2023. The number of verified paid aesthetic treatments performed surpassed 81,500, compared with approximately 5,000 in the same period of 2023.
- The number of active users, defined as those who visited the aesthetic centers at least once during the 12-month period ending on the last day of the respective quarter, exceeded 52,000, compared with approximately 2,900 users during the corresponding period in 2023.
- As of December 31, 2024, So-Young had 19 aesthetic centers in nine major cities, including
Beijing ,Shanghai ,Guangzhou ,Shenzhen ,Hangzhou ,Chengdu ,Wuhan ,Chongqing andChangsha , all of which are fully operational. Among them, 11 centers have achieved positive monthly operating cash flow. The following table shows the revenues generated by So-Young aesthetic centers, categorized by their phase of development:
Phase (The length of time since establishment) | Number of | Revenue | Average Revenue per |
Ramp-up (0-3 months) | 4 | 2,875,000 | 719,000 |
Growth (4-12 months) | 14 | 64,277,000 | 4,591,000 |
Maturity (over 12 months) | 1 | 14,115,000 | 14,115,000 |
- The number of institutions So-Young served with supply chain solutions for injectables grew to over 1,200 this quarter. Shipments of Elasty injectable products reached approximately 52,000 units, compared with 53,000 in the same period of 2023.
Fiscal Year 2024 Financial Highlights
- Total revenues were
RMB1,466.7 million (US ) in the full year 2024, compared with$200.9 million RMB1,498.0 million in the prior year. - Net loss attributable to So-Young International Inc. was
RMB589.5 million (US ) in the full year 2024, primarily driven by a one-time goodwill impairment charge of$80.8 million RMB540.0 million (US ) for the Company's subsidiary, Wuhan Miracle. This compared with a net income attributable to So-Young International Inc. of$74.0 million RMB21.3 million in the prior year. - Non-GAAP net loss attributable to So-Young International Inc. was
RMB4.7 million (US ) in the full year 2024, compared with a non-GAAP net income attributable to So-Young International Inc. of$0.6 million RMB58.0 million in the prior year.
[1] This press release contains translations of certain Renminbi (RMB) amounts into |
[2] Non-GAAP net income/(loss) attributable to So-Young International Inc. is defined as net income/(loss) attributable to So-Young International Inc. excluding share-based compensation expenses, impairment of goodwill attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release. |
Declaration of Special Dividend
The board of directors of the Company has declared a special cash dividend of
Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, "Despite a challenging environment, we remain focused on executing our transformation strategy. Our investments in vertical integration and business diversification are beginning to take shape, reinforcing our competitive positioning in the evolving medical aesthetics landscape. The opportunity created by demand for standardized high-quality, cost-effective medical aesthetic products and services remains enormous, one that we are uniquely positioned to capitalize on. As of December 31, 2024, we expanded our network to 19 aesthetic centers across nine major cities, with 11 of them already generating positive operating cash flow. Customer retention rates continue to maintain at approximately
Mr. Hui Zhao, Chief Financial Officer of So-Young, added, "Our fourth-quarter results demonstrate the resilience of our business and strategic agility to adapt to market changes. The expansion of our center network is noticeably improving the customer experience and laying the groundwork for long-term, sustainable growth. We continued to drive operational efficiency improvements, carefully control costs, and invest in scaling and strengthening the synergies between our businesses. While the near-term environment remains dynamic, we are confident that our strategic direction will create long-term value for both our customers and shareholders."
Fourth Quarter 2024 Financial Results
Revenues
Total revenues were
- Information, reservation services and other revenues were
RMB201.5 million (US ), a decrease of$27.6 million 27.7% fromRMB278.5 million in the same period of 2023. The decrease was primarily due to a decrease in revenues generated by So-Young Prime. - Aesthetic treatment services[3] revenues were
RMB81.3 million (US ), an increase of$11.1 million 701.6% fromRMB10.1 million in the same period of 2023. The increase was primarily due to the business extension of the branded aesthetic centers. - Sales of medical products and maintenance services were
RMB86.4 million (US ), a decrease of$11.8 million 15.2% fromRMB101.9 million in the same period of 2023, primarily due to a decrease in the order volume for medical equipment.
Cost of Revenues
Cost of revenues was
- Cost of information, reservation services and others[4] were
RMB44.5 million (US ), a decrease of$6.1 million 48.2% fromRMB86.0 million in the fourth quarter of 2023. The decrease was primarily due to a decrease in costs associated with So-Young Prime. - Cost of aesthetic treatment services were
RMB65.2 million (US ), an increase of$8.9 million 702.3% fromRMB8.1 million in the fourth quarter of 2023. The increase was primarily due to the business extension of the branded aesthetic centers. - Cost of medical products sold and maintenance services were
RMB43.3 million (US ), a decrease of$5.9 million 0.5% fromRMB43.6 million in the fourth quarter of 2023. The decrease was primarily due to a decrease in costs associated with the sales of cosmetic injectables.
[3] In the fourth quarter of 2024, in light of the better monitoring business development of branded aesthetic centers, the previous line item information services and others was separated into two line items, which are aesthetic treatment services and information services and others. And the Company grouped the revenue generated from information services and others and reservation services, which is renamed as information, reservation services and others. |
The revenue generated from aesthetic treatment services was previously reported in line item of information services and others. The information, reservation services and others for prior periods and the year of 2023 have also been retrospectively updated. The amount reclassified from previous line item information services and others to aesthetic treatment services are |
[4] In the fourth quarter of 2024, the previous line item cost of services and others was separated into two line items, which are cost of aesthetic treatment services and cost of information, reservation services and others. Cost of aesthetic treatment services primarily consists of expenditures relating to aesthetic treatment services in branded aesthetic centers, and the remaining cost of services and others is reclassified into cost of information, reservation services and others. The cost of aesthetic treatment services and cost of information, reservation services and others for prior periods and the year of 2023 have also been retrospectively reclassified. |
Operating Expenses
Total operating expenses were
- Sales and marketing expenses were
RMB134.0 million (US ), an increase of$18.4 million 6.2% fromRMB126.2 million in the fourth quarter of 2023. The increase was primarily due to an increase in payroll costs. Sales and marketing expenses included share-based compensation expenses ofRMB0.2 million (US ), compared with$0.0 million RMB2.8 million in the corresponding period of 2023. - General and administrative expenses were
RMB98.4 million (US ), an increase of$13.5 million 13.6% fromRMB86.7 million in the fourth quarter of 2023. The increase was due to an increase in professional services fees and allowance for credit losses. General and administrative expenses included share-based compensation expenses ofRMB1.7 million (US ), compared with$0.2 million RMB13.2 million in the corresponding period of 2023. - Research and development expenses were
RMB42.8 million (US ), a decrease of$5.9 million 5.0% fromRMB45.0 million in the fourth quarter of 2023. The decrease was primarily attributable to improvements in staff efficiency. Research and development expenses included share-based compensation expenses ofRMB0.2 million (US ), compared with$0.0 million RMB1.6 million in the corresponding period of 2023. - Impairment of goodwill was
RMB540.0 million (US ), representing the amount by which the carrying amount of certain asset exceeds their fair value in relation to the acquiring subsidiary, based on an annual goodwill impairment assessment.$74.0 million
Income Tax (Expenses)/Benefits
Income tax expenses were
Net (Loss)/Income Attributable to So-Young International Inc.
Net loss attributable to So-Young International Inc. was
Non-GAAP Net (Loss)/Income Attributable to So-Young International Inc.
Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, impairment of goodwill attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments, was
Basic and Diluted (Loss)/Earnings per ADS
Basic and diluted loss per ADS attributable to ordinary shareholders were
Fiscal Year 2024 Financial Results
Revenues
Total revenues were
- Information, reservation services and other revenues were
RMB929.5 million (US ), a decrease of$127.3 million 19.3% fromRMB1,151.5 million in fiscal year 2023. The decrease was primarily due to a decrease in average revenue per paying medical service provider. - Aesthetic treatment services revenues were
RMB169.3 million (US ), an increase of$23.2 million 1206.1% fromRMB13.0 million in fiscal year 2023. The increase was primarily due to the business extension of the branded aesthetic centers. - Sales of medical products and maintenance services were
RMB368.0 million (US ), an increase of$50.4 million 10.3% fromRMB333.5 million in fiscal year 2023, primarily due to an increase in sales of cosmetic products.
Cost of Revenues
Cost of revenues were
- Cost of information, reservation services and others were
RMB252.8 million (US ), a decrease of$34.6 million 32.8% fromRMB376.0 million in fiscal year 2023. The decrease was primarily due to a decrease in costs associated with So-Young Prime. - Cost of aesthetic treatment services were
RMB131.6 million (US ), an increase of$18.0 million 1271.2% fromRMB9.6 million in fiscal year 2023. The increase was primarily due to the business extension of the branded aesthetic centers. - Cost of medical products sold and maintenance services were
RMB183.2 million (US ), an increase of$25.1 million 15.4% fromRMB158.8 million in fiscal year 2023. The increase was primarily due to an increase in costs associated with the sales of cosmetic products.
Operating Expenses
Total operating expenses were
- Sales and marketing expenses were
RMB494.5 million (US ), a decrease of$67.7 million 5.0% fromRMB520.5 million in fiscal year 2023. The decrease was primarily due to a decrease in expenses associated with branding and user acquisition activities. Sales and marketing expenses for fiscal year 2024 included share-based compensation expenses ofRMB0.7 million (US ), compared to$0.1 million RMB5.7 million in fiscal year 2023. - General and administrative expenses were
RMB324.1 million (US ), an increase of$44.4 million 11.5% fromRMB290.8 million in fiscal year 2023. The increase was due to business extension of the branded aesthetic centers and the increase in allowance for credit losses. General and administrative expenses for 2024 included share-based compensation expenses ofRMB29.5 million (US ), compared to$4.0 million RMB23.6 million in fiscal year 2023. - Research and development expenses were
RMB165.0 million (US ), a decrease of$22.6 million 18.9% fromRMB203.5 million in fiscal year 2023. The decrease was primarily attributable to improvements in staff efficiency. Research and development expenses for 2024 included share-based compensation expenses ofRMB2.2 million (US ), compared to$0.3 million RMB5.3 million in fiscal year 2023. - Impairment of goodwill was
RMB540.0 million (US ), representing the amount by which the carrying amount of certain asset exceeds their fair value in relation to the acquiring subsidiary, based on an annual goodwill impairment assessment.$74.0 million
Income Tax Benefits
Income tax benefits were
Net (Loss)/Income Attributable to So-Young International Inc.
Net loss attributable to So-Young International Inc. was
Non-GAAP Net (Loss)/Income Attributable to So-Young International Inc.
Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, impairment of goodwill attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments, was
Basic and Diluted (Loss)/Earnings per ADS
Basic and diluted loss per ADS attributable to ordinary shareholders were
Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments
As of December 31, 2024, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were
Business Outlook
For the first quarter of 2025, So-Young expects total revenues to be between
Non-GAAP Financial Measures
To supplement the financial measures prepared in accordance with generally accepted accounting principles in
The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses (i) that are not expected to result in cash payments or (ii) that are non-recurring in nature or may not be indicative of the Company's core operating results and business outlook. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses, the impairment of goodwill, impairment of long-term investment and allowance for credit loss from loans to investees are non-cash in nature. Gain/(loss) on disposal of long-term investment and fair value change of long-term investment are non-recurring in nature. And, in substance, both impairment of long-term investment and allowance for credit loss from loans to investees are impairment of investment. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses, impairment of goodwill, impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.
Conference Call Information
So-Young's management will hold an earnings conference call on Friday, March 28, 2025, at 7:30 AM
International: | +1-412-902-4272 |
Mainland China: | 4001-201203 |
US: | +1-888-346-8982 |
Hong Kong: | +852-301-84992 |
Passcode: | So-Young International Inc. |
A telephone replay will be available two hours after the conclusion of the conference call through 23:59
International: | +1-412-317-0088 |
US: | +1-877-344-7529 |
Passcode: | 8460187 |
Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.
About So-Young International Inc.
So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company") is the leading aesthetic treatment platform in
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the
For more information, please contact:
So-Young
Investor Relations
Ms. Mona Qiao
Phone: +86-10-8790-2012
E-mail: ir@soyoung.com
Christensen
In
Ms. Dee Wang
Phone: +86-10-5900-1548
E-mail: dee.wang@christensencomms.com
In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: linda.bergkamp@christensencomms.com
SO-YOUNG INTERNATIONAL INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except for share and per share data) | |||||
As of | |||||
December 31, | December 31, | December 31, | |||
2023 | 2024 | 2024 | |||
RMB | RMB | US$ | |||
Assets | |||||
Current assets: | |||||
Cash and cash equivalents | 426,119 | 587,749 | 80,521 | ||
Restricted cash and term deposits | 14,695 | 66,367 | 9,092 | ||
Trade receivables | 57,219 | 98,774 | 13,532 | ||
Inventories | 118,924 | 151,754 | 20,790 | ||
Receivables from online payment platforms | 23,158 | 24,255 | 3,323 | ||
Amounts due from related parties | 9,212 | 1,218 | 167 | ||
Term deposits and short-term investments | 900,823 | 599,041 | 82,068 | ||
Prepayment and other current assets | 171,774 | 195,202 | 26,743 | ||
Total current assets | 1,721,924 | 1,724,360 | 236,236 | ||
Non-current assets: | |||||
Long-term investments | 261,016 | 280,281 | 38,398 | ||
Intangible assets | 145,253 | 126,615 | 17,346 | ||
Goodwill | 540,693 | 684 | 94 | ||
Property and equipment, net | 116,782 | 155,352 | 21,283 | ||
Deferred tax assets | 78,034 | 84,950 | 11,638 | ||
Operating lease right-of-use assets | 118,408 | 162,764 | 22,299 | ||
Other non-current assets | 232,455 | 200,152 | 27,421 | ||
Total non-current assets | 1,492,641 | 1,010,798 | 138,479 | ||
Total assets | 3,214,565 | 2,735,158 | 374,715 | ||
Liabilities | |||||
Current liabilities: | |||||
Short-term borrowings | 29,825 | 69,771 | 9,559 | ||
Taxes payable | 56,894 | 61,862 | 8,475 | ||
Contract liabilities | 103,374 | 76,579 | 10,491 | ||
Salary and welfare payables | 86,290 | 111,396 | 15,261 | ||
Amounts due to related parties | 388 | 477 | 65 | ||
Accrued expenses and other current liabilities | 233,913 | 265,216 | 36,334 | ||
Operating lease liabilities-current | 29,739 | 44,905 | 6,152 | ||
Total current liabilities | 540,423 | 630,206 | 86,337 | ||
Non-current liabilities: | |||||
Operating lease liabilities-non current | 86,210 | 125,200 | 17,152 | ||
Deferred tax liabilities | 25,082 | 19,758 | 2,707 | ||
Other non-current liabilities | 1,536 | 1,264 | 173 | ||
Total non-current liabilities | 112,828 | 146,222 | 20,032 | ||
Total liabilities | 653,251 | 776,428 | 106,369 |
SO-YOUNG INTERNATIONAL INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued) (Amounts in thousands, except for share and per share data) | ||||||
Shareholders' equity: | ||||||
Treasury stock | (358,453) | (376,690) | (51,606) | |||
Class A ordinary shares ( | 238 | 253 | 35 | |||
Class B ordinary shares ( | 37 | 37 | 5 | |||
Additional paid-in capital | 3,080,433 | 3,069,799 | 420,561 | |||
Statutory reserves | 33,855 | 40,552 | 5,556 | |||
Accumulated deficit | (330,166) | (926,390) | (126,915) | |||
Accumulated other comprehensive income | 18,185 | 31,560 | 4,324 | |||
Total So-Young International Inc. shareholders' equity | 2,444,129 | 1,839,121 | 251,960 | |||
Non-controlling interests | 117,185 | 119,609 | 16,386 | |||
Total shareholders' equity | 2,561,314 | 1,958,730 | 268,346 | |||
Total liabilities and shareholders' equity | 3,214,565 | 2,735,158 | 374,715 |
SO-YOUNG INTERNATIONAL INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except for share and per share data) | ||||||||||||
For the Three Months Ended | For the Fiscal Year Ended | |||||||||||
December 31, 2023 | December 31, 2024 | December 31, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2024 | |||||||
RMB | RMB | US$ | RMB | RMB | US$ | |||||||
Revenues: | ||||||||||||
Information, reservation services and others | 278,529 | 201,512 | 27,607 | 1,151,532 | 929,455 | 127,335 | ||||||
Aesthetic treatment services | 10,138 | 81,267 | 11,134 | 12,959 | 169,263 | 23,189 | ||||||
Sales of medical products and maintenance services | 101,899 | 86,432 | 11,841 | 333,538 | 367,980 | 50,413 | ||||||
Total revenues | 390,566 | 369,211 | 50,582 | 1,498,029 | 1,466,698 | 200,937 | ||||||
Cost of revenues: | ||||||||||||
Cost of information, reservation services and others | (85,951) | (44,518) | (6,099) | (375,986) | (252,841) | (34,639) | ||||||
Cost of aesthetic treatment services | (8,128) | (65,208) | (8,933) | (9,596) | (131,580) | (18,026) | ||||||
Cost of medical products sold and maintenance services | (43,555) | (43,325) | (5,936) | (158,754) | (183,164) | (25,093) | ||||||
Total cost of revenues | (137,634) | (153,051) | (20,968) | (544,336) | (567,585) | (77,758) | ||||||
Gross profit | 252,932 | 216,160 | 29,614 | 953,693 | 899,113 | 123,179 | ||||||
Operating expenses: | ||||||||||||
Sales and marketing expenses | (126,175) | (134,045) | (18,364) | (520,451) | (494,493) | (67,745) | ||||||
General and administrative expenses | (86,668) | (98,420) | (13,483) | (290,765) | (324,073) | (44,398) | ||||||
Research and development expenses | (44,993) | (42,753) | (5,857) | (203,524) | (165,030) | (22,609) | ||||||
Impairment of goodwill | — | (540,009) | (73,981) | — | (540,009) | (73,981) | ||||||
Total operating expenses | (257,836) | (815,227) | (111,685) | (1,014,740) | (1,523,605) | (208,733) | ||||||
Loss from operations | (4,904) | (599,067) | (82,071) | (61,047) | (624,492) | (85,554) | ||||||
Other income/(expenses): | ||||||||||||
Investment income, net | 1,135 | 7,623 | 1,044 | 12,004 | 11,020 | 1,510 | ||||||
Interest income, net | 10,820 | 8,237 | 1,128 | 48,843 | 46,507 | 6,371 | ||||||
Exchange gains/(losses) | 389 | (763) | (105) | (662) | 112 | 15 | ||||||
Impairment of long-term investment | (444) | (7,350) | (1,007) | (444) | (7,350) | (1,007) | ||||||
Share of losses of equity method investee | (2,031) | (3,413) | (468) | (12,723) | (15,015) | (2,057) | ||||||
Others, net | 3,424 | (11,103) | (1,521) | 21,898 | 1,131 | 155 | ||||||
Income/(Loss) before tax | 8,389 | (605,836) | (83,000) | 7,869 | (588,087) | (80,567) | ||||||
Income tax benefits/(expenses) | 10,835 | (2,126) | (291) | 18,075 | 905 | 124 | ||||||
Net income/(loss) | 19,224 | (607,962) | (83,291) | 25,944 | (587,182) | (80,443) | ||||||
Net (income)/loss attributable to noncontrolling interests | (1,723) | 386 | 53 | (4,664) | (2,345) | (321) | ||||||
Net income/(loss) attributable to So-Young International Inc. | 17,501 | (607,576) | (83,238) | 21,280 | (589,527) | (80,764) |
SO-YOUNG INTERNATIONAL INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued) (Amounts in thousands, except for share and per share data)
| ||||||||||||
For the Three Months Ended | For the Fiscal Year Ended | |||||||||||
December | December | December | December | December | December | |||||||
RMB | RMB | US$ | RMB | RMB | US$ | |||||||
Net earnings/(loss) per ordinary share | ||||||||||||
Net earnings/(loss) per ordinary share attributable to ordinary shareholder - basic | 0.23 | (7.70) | (1.05) | 0.27 | (7.43) | (1.02) | ||||||
Net earnings/(loss) per ordinary share attributable to ordinary shareholder - | 0.23 | (7.70) | (1.05) | 0.27 | (7.43) | (1.02) | ||||||
Net earnings/(loss) per ADS attributable to ordinary shareholders - basic (13 | 0.18 | (5.92) | (0.81) | 0.21 | (5.72) | (0.78) | ||||||
Net earnings/(loss) per ADS attributable to ordinary shareholders - diluted (13 | 0.18 | (5.92) | (0.81) | 0.21 | (5.72) | (0.78) | ||||||
Weighted average number of ordinary shares used in computing earnings/(loss) | 76,584,151 | 78,905,617 | 78,905,617 | 77,646,899 | 79,384,454 | 79,384,454 | ||||||
Weighted average number of ordinary shares used in computing earnings/(loss) | 77,011,890 | 78,905,617 | 78,905,617 | 78,054,950 | 79,384,454 | 79,384,454 | ||||||
Share-based compensation expenses included in: | ||||||||||||
Cost of revenues | (165) | (34) | (5) | (1,800) | (289) | (40) | ||||||
Sales and marketing expenses | (2,830) | (239) | (33) | (5,680) | (659) | (90) | ||||||
General and administrative expenses | (13,190) | (1,731) | (237) | (23,590) | (29,527) | (4,045) | ||||||
Research and development expenses | (1,615) | (211) | (29) | (5,251) | (2,180) | (299) | ||||||
* Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted. |
SO-YOUNG INTERNATIONAL INC. Reconciliation of GAAP and Non-GAAP Results (Amounts in thousands, except for share and per share data) | ||||||||||||
For the Three Months Ended | For the Fiscal Year Ended | |||||||||||
December | December | December | December | December | December | |||||||
RMB | RMB | US$ | RMB | RMB | US$ | |||||||
GAAP loss from operations | (4,904) | (599,067) | (82,071) | (61,047) | (624,492) | (85,554) | ||||||
Add back: Share-based compensation expenses | 17,800 | 2,215 | 304 | 36,321 | 32,655 | 4,474 | ||||||
Add back: Impairment of goodwill | — | 540,009 | 73,981 | — | 540,009 | 73,981 | ||||||
Non-GAAP income/(loss) from operations | 12,896 | (56,843) | (7,786) | (24,726) | (51,828) | (7,099) | ||||||
GAAP net income/(loss) attributable to So-Young International Inc. | 17,501 | (607,576) | (83,238) | 21,280 | (589,527) | (80,764) | ||||||
Add back: Share-based compensation expenses | 17,800 | 2,215 | 304 | 36,321 | 32,655 | 4,474 | ||||||
Add back: Impairment of goodwill attributable to So-Young International Inc. | — | 540,009 | 73,981 | — | 540,009 | 73,981 | ||||||
Add back: Impairment of long-term investment attributable to So-Young | 444 | 7,350 | 1,007 | 444 | 7,350 | 1,007 | ||||||
Add back: Allowance for credit loss from loans to investees attributable to So- | — | 13,843 | 1,896 | — | 13,843 | 1,896 | ||||||
Reversal: Gain on disposal of long-term investment and fair value change of | — | (7,791) | (1,067) | — | (7,791) | (1,067) | ||||||
Reversal: Tax effects on non-GAAP adjustments (1) | — | (1,276) | (175) | — | (1,276) | (175) | ||||||
Non-GAAP net income/(loss) attributable to So-Young International Inc. | 35,745 | (53,226) | (7,292) | 58,045 | (4,737) | (648) |
(1) To adjust the income tax effects of non-GAAP adjustments, which is primarily related to allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment. Other non-GAAP adjustment items have no tax effect, because full valuation allowances were provided for related deferred tax assets as it is more-likely-than-not they will not be realized. |
View original content:https://www.prnewswire.com/news-releases/so-young-reports-unaudited-fourth-quarter-and-fiscal-year-2024-financial-results-302414207.html
SOURCE So-Young International Inc.